-transparent.png){kind=logo}
Treatment with amikacin was evaluated in 15 patients with gram-negative bacteremia. The sources of sepsis were urinary tract (in six patients), abdomen (in five) and miscellaneous sites (in four). Sixteen bacterial pathogens were recovered, including three gentamicin-resistant organisms. All isolates were susceptible to amikacin. Eleven of the 14 patients who could be evaluated fulfilled the criteria for cure, including the three patients with gentamicin-resistant organisms. Three patients failed to respond to amikacin therapy. Monitoring untoward effects revealed eighth nerve toxicity in one patient and nephrotoxicity in one patient. These results indicate that amikacin is effective in the treatment of patients with gram-negative bacteremia, even when caused by gentamicin-resistant bacteria.
F P Tally, and
S L Gorbach
June 1977,
The American journal of medicine,
F P Tally, and
S L Gorbach
February 1977,
JAMA,
F P Tally, and
S L Gorbach
December 1991,
Infectious disease clinics of North America,
F P Tally, and
S L Gorbach
May 1978,
Archives of internal medicine,
F P Tally, and
S L Gorbach
December 1975,
Annals of internal medicine,
F P Tally, and
S L Gorbach
February 1969,
The Johns Hopkins medical journal,
F P Tally, and
S L Gorbach
January 1972,
Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
F P Tally, and
S L Gorbach
January 1993,
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,
